Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin or Chlorthalidone: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Overall Study Question
These investigators evaluated the differences in long-term outcomes when hypertensive patients were treated with either doxazosin or chlorthalidone.
24,335 patients mean age 67 (47% women) with hypertension (>140/90) and at least one other coronary heart disease risk factor.
Chlorthalidone 12.5 or 25 mg po daily versus doxazosin 2,4, and 8 mg po daily.
The doxazosin arm was stopped early after 3.3 years.
|Fatal and nonfatal MI (%)||All deaths (%)||CHD death, non-fatal MI, revascularization, and angina (%)||CHF (%)||Strokes (%)|
|Relative Risk Reduction||NSS||8||44||31|
|Absolute Risk Reduction||1.1||3.6||0.6|
|NNT/NNH over 3.3 years||91||28||167|
NNT = numbers needed to treat, NNH = numbers needed to harm, NSS = not statistically significant
Systolic blood pressure was approximately 2-3 mmHg lower in the chlorthalidone group, thre was no difference in the diastolic blood pressure between groups. Cholesterol was 0.2 mmol/L lower, potassium was 0.4 mmol/L higher, and mean serum glucose was 0.2 mmol/L lower in the doxazosin group.
How does this study contribute to the drug therapy of patients with hypertension?
This study shows that despite similar changes in surrogate markers, chlorthalidone patients had fewer CHD death, non-fatal, MI, revascularization, and angina (1.1% absolute difference), CHF (3.6 % absolute difference) and strokes (0.6% absolute difference) than patients treated with doxazosin.
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-75.